Needham Reiterates Buy on NextCure, Maintains $4 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum has reiterated a Buy rating on NextCure (NASDAQ:NXTC) and maintained a $4 price target.
August 02, 2024 | 12:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Gil Blum has reiterated a Buy rating on NextCure and maintained a $4 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and the maintenance of a $4 price target by a reputable analyst can boost investor confidence in NextCure, potentially leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100